Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy, Safety, and Tolerability of 8% Progesterone Vaginal Gel in Preventing Preterm Delivery in Pregnant Women at Increased-Risk for Preterm Delivery

NCT00086177 is registered in ClinicalTrials.gov with Juniper Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00086177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00086177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy, Safety, and Tolerability of 8% Progesterone Vaginal Gel in Preventing Preterm Delivery in Pregnant Women at Increased-Risk for Preterm Delivery
Lead sponsor
Juniper Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2004
Completion date
March 31, 2009
Enrollment
636 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

pregnancy